BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Pfizer’s JAK Inhibitor Xeljanz Racks Up Another FDA Win

  The FDA’s approval of Xeljanz is based on Pfizer’s Phase III multicenter, double-blind, placebo-controlled study. Here are more details about the study.

  December 15, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Lilly UC Treatment Holds Edge in Maintenance Study, Setting Up BLA

  These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.

  December 15, 2021

   · 

  3 min read

   · 

  Sreetama Dutt
• 

  Drug Development

  Notch Another Win for AbbVie’s Rinvoq, This Time in Psoriatic Arthritis

  The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.

  December 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  Mythic Therapeutics Scores $103 Million to Make “Safer and Smarter” ADCs

  Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).

  December 15, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Omicron Surges Across the World While Vaccines Struggle to Contain It

  Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.

  December 15, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  It’s Back to the Drawing Board for Generation Bio’s Hemophilia A Program

  Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.

  December 15, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Career Advice

  How to Answer Some Tricky Interview Questions

  It’s no secret that employers ask tricky interview questions. But what do you do if you find yourself fumbling for words to answer these tricky questions?

  December 15, 2021

   · 

  4 min read

   · 

  Hannah Harshman
• 

  BioMidwest

  Eli Lilly’s Two-Year Ambition Includes Alzheimer’s Approvals

  Eli Lilly and Company’s projections for next year exceed Wall Street projections for the company, predicting 2022 revenue of $27.8 billion to $28.3 billion.

  December 15, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Greenlights BMS’s Orencia for Acute GVHD – Partly on RWE

  The FDA said Orencia is the first drug approved as prophylaxis for aGVHD prevention that included real-world evidence as one component of clinical efficacy.

  December 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Money on the Move: December 8 – 14

  During a season of giving, investors were extra generous to these biotech companies this week.

  December 15, 2021

   · 

  3 min read

   · 

  Kate Goodwin